Introduction: Millions of people were threatened in COVID-19 pandemic. Vaccination was the most effective global strategy to fight pandemic. People with cystic fibrosis (pwCF) were considered a high-risk group. In Serbia vaccination was prioritised for them.
Aim: The aim of the study is to establish prevalences of vaccination against SARS-CoV2 in patients with CF, analyse morbidity and outcomes of the disease
Results: Of nineteen adult patients in the IPBV there is 10 females and 9 males. The mean age of patients is 29.5 years (min 20, max 44). In total 12 adult CF patients (63%) were vaccinated. Nine of vaccinated (81%) received Pfizer-BioNTech COVID-19 vaccine, 2 (18%) SPUTNIK V Gam-COVID and 1 (18%) received Sinopharm vaccine (0,09). A total of 6 patients (31%) tested positive for the SARS CoV2 virus. Of this number, five patients were treated at home. Infected patients had a mild clinical form of the disease and there were no fatal outcomes. One patient (0,05%) was hospitalized and required oxygen support. This patient was not vaccinated.
Conclusions: COVID-19 vaccine uptake in our cohort was similar comparing to general population in Serbia, but it was lower than WHO recommendation. The outcomes of cases with SARS-CoV-2 infection in pwCF were good. The hospitalization rate was very low. The absence of mortality may be linked to the relatively low incidence of of SARS-CoV-2 infection. This could be attributed to effective shielding techniques and infection control measures. The direct vaccination guidance for pwCF is imoportant to educate them about safety and efficacy of the vaccine.